References
- O’Connor OA, Horwitz S, Hamlin P, et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 2009;27:4357–4364.
- Zain J, O’Connor O. Pralatrexate: basic understanding and clinical development. Expert Opin Pharmacother 2010;11:1705–1714.
- O’Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011;29:1182–1189.
- Horwitz SM, Kim YH, Foss F, et al. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Blood 2012;119:4115–4122.
- Serova M, Bieche I, Sablin MP, et al. Single agent and combination studies of pralatrexate and molecular correlates of sensitivity. Br J Cancer 2011;104:272–280.
- Allos Therapeutics, Incorporated. Folotyn (pralatrexate) for injection: US prescribing information [online]. Available from: http://www.folotyn.com/sites/default/files/pdf/Folotyn_PI.pdf
- Browman GP, Goodyear MD, Levine MN, et al. Modulation of the antitumor effect of methotrexate by low-dose leucovorin in squamous cell head and neck cancer: a randomized placebo-controlled clinical trial. J Clin Oncol 1990;8:203–208.
- Kindler HL, Belani CP, Herndon JE 2nd, et al. Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B. Cancer 1999;86:1985–1991.
- Takimoto CH, Hammond-Thelin LA, Latz JE, et al. Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer. Clin Cancer Res 2007;13:2675–2683.
- Smit EF, Mattson K, von Pawel J, et al. ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study. Ann Oncol 2003;14:455–460.
- Lee JS, Libshitz HI, Fossella FV, et al. Improved therapeutic index by leucovorin of edatrexate, cyclophosphamide, and cisplatin regimen for non-small-cell lung cancer. J Natl Cancer Inst 1992;84: 1039–1040.
- Haddad PA. Efficacy of short oral leucovorin rescue (SOLR) in managing recurrent pralatrexate (Folotyn) induced mucositis (RPIM) despite dose reduction. Blood 2011;118(Suppl. 1): Abstract 4745.
- Boarman DM, Allegra CJ. Intracellular metabolism of 5-formyl tetrahydrofolate in human breast and colon cell lines. Cancer Res 1992;52:36–44.
- Mayne Pharmaceuticals. Leucovorin calcium for injection: US prescribing information [online]. Available from: http://patient.cancerconsultants.com/druginserts/Leucovorininj.pdf